Theranostics Explained: Integrated Centers Combine Diagnosis and Targeted Radiotherapy

What Is Theranostics and How Does It Treat Cancer?

Theranostics is a precision oncology approach that links diagnosis and therapy through a shared molecular target. Clinicians first administer a radiolabeled tracer that binds to a receptor expressed on cancer cells — for example, prostate-specific membrane antigen (PSMA) on prostate cancer or somatostatin receptors on neuroendocrine tumors. A PET scan reveals where the tracer accumulates, confirming that the tumor carries the target. A therapeutic dose using the same targeting molecule, but labeled with a beta- or alpha-emitting isotope such as lutetium-177 or actinium-225, then delivers radiation directly to those cells while sparing healthy tissue.

The approach has transformed management of metastatic castration-resistant prostate cancer and advanced gastroenteropancreatic neuroendocrine tumors. The FDA has approved lutetium-177 vipivotide tetraxetan (Pluvicto) for PSMA-positive prostate cancer and lutetium-177 DOTATATE (Lutathera) for somatostatin receptor-positive neuroendocrine tumors. Research pipelines are expanding theranostic strategies into breast, pancreatic, and pediatric cancers, where targets such as CXCR4, FAP, and GD2 are under active investigation.

Why Do Integrated Theranostics Centers Matter for Patients?

Delivering theranostic care requires tightly coordinated infrastructure: cyclotrons or generators to produce short-half-life isotopes, radiochemistry labs, PET/CT scanners, shielded infusion suites, and specialists in nuclear medicine, medical oncology, and radiation safety. When these capabilities are fragmented across institutions, patients face delays, duplicated scans, and treatment interruptions. The announced collaboration between The University of Kansas Health System, University of Kansas Medical Center, Children's Mercy and BAMF Health reflects a broader national trend toward consolidating these services in destination centers.

Integration particularly benefits pediatric patients, who represent a small but underserved theranostics population. Children's Mercy's involvement signals expanded access to targeted radioligand therapy for neuroblastoma and other childhood cancers, which have historically lacked dedicated pediatric-capable infrastructure. Co-locating adult and pediatric programs also accelerates enrollment in clinical trials, where combined volumes make statistically meaningful studies feasible for rare tumors.

What Are the Risks and Limitations of Theranostic Therapy?

Theranostics is not a universal cancer cure. Eligibility depends on pre-treatment imaging demonstrating sufficient target expression — patients whose tumors lack PSMA or somatostatin receptors, for example, will not benefit. Common adverse effects include transient bone marrow suppression, fatigue, nausea, and off-target radiation to the salivary glands and kidneys, which must be monitored over time. Long-term risks such as secondary malignancies are still being characterized as follow-up data mature.

Access remains uneven. Radiopharmaceuticals have short shelf lives, require specialized handling, and are expensive, which concentrates treatment at academic centers. Insurance coverage, reimbursement complexity, and isotope supply shortages — particularly for lutetium-177 and actinium-225 — can delay care. Expanding integrated centers is one strategy to address these bottlenecks, but sustained investment in isotope production and workforce training will be essential to scale theranostics nationally.